Radioisotope Market Size to Reach USD 13.78 Billion by 2035

Radioisotope Market: USD 6.15 billion in 2025, Shifting from Imaging Volume to Therapy Value

Worldwide, the radioisotope market stood at USD 6.15 billion in 2025, and therapy-led demand puts the market on track for USD 13.78 billion by 2035, a CAGR of 8.40% over 2025–2035. For 2026, the current year, we put the radioisotope market at USD 6.67 billion.

These are our own estimates. We built them isotope by isotope and region by region, then checked them against agency supply data and the disclosed performance of the leading radioligand therapies. We did not take them from other published market studies.

Our central view is that the market is moving from volume to value. Technetium-99m is still used in 80% to 85% of nuclear medicine procedures, according to the OECD Nuclear Energy Agency, and it remains the largest isotope family with a 31.6% share. Yet it grows at only 2.85% a year. Lutetium-177, the isotope behind approved radioligand therapies, holds a 13.4% share and is the fastest-growing isotope at 17.15% a year.

What do we count as a radioisotope sale?

We count radioactive isotopes and isotope-based products sold to hospitals, radiopharmacies, research bodies and industrial users, valued at the selling price of isotope producers and radiopharmaceutical suppliers. Therapy isotopes are counted at isotope and precursor value, not at the price of the branded drug.

The market includes:

• Molybdenum-99/technetium-99m generators, kits and unit doses for SPECT imaging.
• Cyclotron-made PET isotopes such as fluorine-18 and generator-made gallium-68.
• Therapy isotopes, including lutetium-177, iodine-131 and actinium-225.
• Sealed sources such as cobalt-60 and iridium-192 for sterilization, radiography and gauging.

We leave out three things:

• Stable isotopes and enriched target materials sold before irradiation.
• Imaging scanners, cyclotrons and hot cells, which belong to equipment markets.
• Nuclear power fuel and isotopes used only for weapons or defence work.

Why does a value shift matter more than procedure counts?

A diagnostic technetium-99m dose is cheap and its use grows slowly in mature health systems. A therapy cycle with lutetium-177 carries far more isotope value, and each patient receives several cycles plus PET scans before and during treatment. Novartis reported that Pluvicto sales rose 43% in 2025, according to its full-year 2025 results. That pace, not the slow rise in bone and heart scans, sets the 8.40% growth rate we use for the whole market.

Report Attributes

How did we size the market?

We used three lenses and kept the estimate only where they agreed:

1. Procedure build. For diagnostic isotopes we combined imaging procedure counts with the isotope value per study, country by country.
2. Therapy build. For lutetium-177 and other therapy isotopes we worked from treated patients, cycles per patient and isotope value per cycle, tested against the disclosed growth of approved radioligand drugs.
3. Supply check. We matched demand against reactor and cyclotron capacity reported by the OECD Nuclear Energy Agency and national programmes, plus sealed-source supply for industry.

The full report sets out the procedure, patient, capacity and price inputs behind each segment, region and year.

Five Isotope Families and Where Each Earns Its Value

Technetium-99m is the largest isotope family with a 31.6% share of 2025 value. Lutetium-177 is the fastest-growing at 17.15% a year, and in our model it overtakes fluorine-18 before 2035.

Why does technetium-99m still lead?

Technetium-99m holds a 31.6% share. Hospitals receive it in molybdenum-99 generators and elute doses on site for heart, bone, kidney and thyroid scans. Prices per dose are low and contracts are long, so revenue is steady but grows only 2.85% a year.

What do other isotopes cover?

Other isotopes hold a 27.5% share and grow at 8.25% a year. The group spans cobalt-60 and iridium-192 sealed sources, gallium-68 generators, iodine-125 seeds, radium-223 and the fast-rising actinium-225.

How fast is fluorine-18 growing?

Fluorine-18 holds a 21.2% share and grows at 8.65% a year. With a half-life under two hours, it is made in regional cyclotrons and sold as PET tracers for cancer staging, neurology and therapy selection.

Why is lutetium-177 the fastest-growing isotope?

Lutetium-177 holds a 13.4% share and grows at 17.15% a year. Approved therapies for prostate and neuroendocrine cancers need several cycles per patient, and new indications keep adding treated patients.

Where does iodine-131 fit?

Iodine-131 holds a 6.3% share. Its demand follows thyroid cancer and hyperthyroidism rather than new drug launches, so it grows only 1.95% a year, the slowest of the five families.

Which applications buy the most?

Diagnostics is the largest application at 57.9% of 2025 value and grows at 5.80% a year. Therapeutics holds 20.3% and is the fastest-growing application at 15.00% a year. Industrial applications hold 15.1%, and research takes the remaining 6.7%, growing at 8.80% a year as alpha-emitter trials scale up.

Who are the end users?

Hospitals and clinics hold a 77.6% share, buying directly or through central radiopharmacies, and grow at 8.84% a year. Industrial sectors hold 15.1% and grow at 5.34%, tied to sterilization and inspection work. Research institutions hold 7.3% and grow at 9.14% a year.

Why Isotope Demand Is Climbing: Therapy Approvals, Imaging Needs and Supply Funding

How does radioligand therapy change the revenue base?

Radioligand therapy has turned the isotope from a diagnostic consumable into the active part of a cancer drug. Lutetium-177 compounds bind to tumour cells that carry a target receptor and deliver radiation from inside. Patients receive several cycles, and each cycle needs a fresh, short-lived batch.

Regulators keep widening the patient pool. In March 2025 the U.S. Food and Drug Administration cleared Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer before chemotherapy, which Novartis said roughly triples the eligible population. Lutathera sales rose 13% in 2025, and Pluvicto rose 43%. In our model, therapeutics holds a 20.3% share and grows at 15.00% a year, more than twice the pace of the market's diagnostic core.

Why do imaging volumes still matter?

Diagnostic imaging is the volume base. The United States alone performs tens of thousands of technetium-99m procedures every day, according to the National Nuclear Security Administration, and the country has relied entirely on imports of molybdenum-99 for decades. Ageing populations add heart, bone and cancer scans every year. Diagnostics holds a 57.9% share and grows at 5.80% a year in our view.

PET imaging grows faster than SPECT. Each therapy patient needs a PSMA or somatostatin-receptor scan first, so fluorine-18 and gallium-68 tracer demand now rides on therapy approvals. Fluorine-18 holds a 21.2% share and grows at 8.65% a year, helped by wider access to PET imaging in Asia and Latin America.

Why are governments paying for isotope supply?

Repeated shortages have made medical isotopes a matter of national supply security. Six research reactors supply about 95% of the world's molybdenum-99, and five of them first operated between 1957 and 1974, according to the OECD Nuclear Energy Agency. When the HFR reactor in the Netherlands shut down in October 2024, shortages followed across several continents.

Public money now backs new capacity on every continent. In September 2025 the NNSA selected SHINE Technologies to finish its molybdenum-99 plant in Janesville, Wisconsin. Since January 2026, U.S. Medicare has paid a per-dose add-on for technetium-99m made from domestic, non-HEU molybdenum-99. Argentina, Brazil, China, Japan and the Netherlands are building reactors or accelerators of their own.

What do new production routes add?

Accelerators and power reactors are opening routes that do not depend on old research reactors. NorthStar makes actinium-225 by electron accelerator in Beloit, Wisconsin. SHINE makes non-carrier-added lutetium-177 at its Cassiopeia plant, and Bruce Power in Canada has doubled its lutetium-177 output capacity since 2022, according to the NEA. More qualified sources let drug developers sign multiyear contracts with two suppliers, which is why we hold other isotopes, led by actinium-225, gallium-68 and cobalt-60, to an 8.25% CAGR.

Where Isotope Supply and Product Strategy Are Heading

Are isotope producers moving into finished drugs?

Yes, and quickly. Producers that once sold bulk isotope now want the margin on the final dose. Curium signed a definitive agreement on 3 August 2026 to acquire Lantheus, according to a Lantheus filing, joining reactor-based supply with a PSMA PET franchise built on fluorine-18. SHINE completed its purchase of the Lantheus SPECT business on 2 January 2026, taking over the TechneLite generator. In our view, fewer and larger groups will control more of the chain from target to patient.

Why are imaging and therapy sold as pairs?

A PET scan picks the patient and a therapy isotope treats them. Fluorine-18 or gallium-68 tracers confirm that a tumour carries the target, and lutetium-177 or actinium-225 agents follow. Hospitals now plan both steps together and add shielded therapy rooms next to PET suites. Suppliers that offer both halves can bundle training, logistics and dosimetry.

Is the pipeline shifting to alpha emitters?

Drug developers are moving from beta emitters such as lutetium-177 toward alpha emitters such as actinium-225, which deposit more energy over a shorter path. Supply has been the brake. NorthStar reported routine commercial-scale actinium-225 production in January 2026, and the FDA accepted its drug master file in April 2026. Eckert & Ziegler is expanding actinium output in Germany and the Czech Republic.

Does manufacturing now decide approvals?

Increasingly, it does. ITM received an FDA complete response letter in August 2026 for its lutetium-177 edotreotide candidate in neuroendocrine tumours. The agency cited chemistry, manufacturing and controls items and findings at a third-party site, and raised no clinical concerns. Developers are responding by building their own dose plants and qualifying backup suppliers, which favours firms with proven good manufacturing practice.

Are radioligand plants moving closer to patients?

Short half-lives reward local production. Novartis opened its third U.S. radioligand therapy plant, in Carlsbad, California, in November 2025, with further sites planned in Florida and Texas. Hospitals in Europe and Asia are also adding in-house regional cyclotrons for PET tracers, so a growing slice of value is made within a few hours' drive of the patient.

What Holds Supply Back: Old Reactors, Short Half-Lives and Thin Staffing

We see four barriers that limit growth: a fragile reactor base, high entry costs, gaps in staff and reimbursement, and substitution risk in industrial uses. None of them stops demand, but each one caps how fast supply can follow it.

How fragile is reactor-based supply?

Very. Molybdenum-99 has a 66-hour half-life and loses about 1% of its activity every hour, so no stockpile can bridge an outage. Most of the reactors that irradiate it are more than 50 years old. The European Commission's SAMIRA action plan says research reactors will need major refurbishment or replacement by 2030, yet PALLAS in Petten, which started construction in September 2025, is not due to run commercially until 2032.

Why are costs so high for new entrants?

Every step needs shielded hot cells, licensed staff and special transport, from target irradiation to the patient. Each change of supplier triggers fresh drug and radiation-safety qualification. Some airlines refuse radioactive cargo, forcing longer routes for products that decay by the hour. Diagnostic reimbursement has often lagged the full cost of supply, which leaves producers little incentive to fund spare capacity.

Do staff and reimbursement gaps cap demand?

Radioligand therapy needs nuclear medicine physicians, physicists, radiopharmacists and shielded rooms that many hospitals lack. Patients outside large cities often have no centre within reach. Hospitals hesitate to build therapy rooms before payers commit, and payers wait for local outcome data. The result is a ceiling on treated patients even where isotope and drug supply exist.

Can non-radioactive technologies take share?

In industry, yes. Electron-beam and X-ray sterilization avoid sealed sources altogether, and digital radiography competes with iridium-192 in some weld inspection. We hold industrial applications to a 5.00% CAGR for that reason, the slowest of the four applications.

Where the Next Gains in Isotope Supply Will Come From

Is there room for a second source of therapy isotopes?

Yes. Trial sponsors need qualified actinium-225 and non-carrier-added lutetium-177 before they can file, and most want two independent sources. SHINE's EU authorization for its Ilumira lutetium-177 precursor in May 2026 shows how a U.S. producer can now serve European drug makers.

Can import-dependent countries build domestic molybdenum-99?

Japan aims to cover about 30% of its molybdenum-99 demand from domestic production by the end of fiscal 2027. Argentina's RA-10 reactor is about 96% complete and is designed to meet about 20% of global molybdenum-99 demand. Brazil's planned RMB reactor targets self-sufficiency from 2031. Suppliers that partner with these programmes gain an early position.

Which therapy networks are underserved?

Gulf states, India and parts of Latin America are opening cancer centres that can give radioligand therapy but lack local dose production. Regional dose manufacturing, staff training and reimbursement support can open markets that global drug makers serve slowly, including for neuroendocrine tumors.

North America Pays the Most, Asia Pacific Adds the Most

Demand follows nuclear medicine capacity and reimbursement, while supply follows reactor geography. North America leads on value; Asia Pacific is the fastest-growing region at 10.56% a year.

North America

North America holds a 41.2% share of 2025 value and grows at 7.96% a year. The United States leads adoption of lutetium-177 therapy and PSMA PET, and federal policy now rewards domestic molybdenum-99. Canada remains a key supplier through Nordion, BWXT Medical and the CANDU reactors that produce about 50% of the world's cobalt-60.

Europe

Europe holds a 27.6% share and grows at 6.86% a year. Germany, France and the United Kingdom have dense nuclear medicine networks, while Belgium, the Netherlands, Czechia and Poland host the reactors that irradiate molybdenum-99 for export. Uneven reimbursement keeps therapy uptake in Southern and Eastern Europe behind the west.

Asia Pacific

Asia Pacific holds a 21.9% share and is the fastest-growing region at 10.56% a year. China has a medical isotope plan running to 2035, and CNNC began commercial lutetium-177 production at Qinshan in 2025. Japan imports nearly all its molybdenum-99, while India, South Korea and Australia combine domestic reactors with growing PET networks.

Latin America

Latin America holds a 4.9% share and grows at 8.76% a year. Argentina's RA-10 reactor and Brazil's RMB project aim to cut import dependence, and Brazil signed its RMB memorandum with INVAP in September 2025. Chile and Colombia are adding PET centres in private hospitals.

Middle East & Africa

Middle East & Africa holds a 4.4% share and grows at 9.26% a year. South Africa's SAFARI-1 is one of the six main molybdenum-99 reactors, so its outages ripple worldwide. Saudi Arabia and other Gulf states are adding cyclotrons and therapy centres under national cancer programmes.

Acquisitions, Approvals and New Plants, 2025–2026

Producers, Drug Makers and Radiopharmacies: Who Supplies Isotopes

Competition runs across three layers that are often confused. Isotope producers irradiate targets and process isotopes. Radiopharmaceutical companies turn them into approved drugs and tracers. Radiopharmacies and distributors deliver unit doses to hospitals each morning.

Who produces the isotopes?

• Curium is a leading producer of molybdenum-99, iodine-131 and lutetium-177, and agreed in August 2026 to acquire Lantheus.
• NTP Radioisotopes processes molybdenum-99 from South Africa's SAFARI-1 reactor.
• Eckert & Ziegler supplies isotopes and sealed sources and is scaling up actinium-225 in Germany and the Czech Republic.
• Nordion supplies cobalt-60 from Canadian power reactors for sterilization.
• SHINE Technologies and NorthStar Medical Radioisotopes lead the new, non-reactor production routes in Wisconsin.

Who turns isotopes into drugs?

Novartis owns Pluvicto and Lutathera, the two leading lutetium-177 therapies, and runs three U.S. radioligand plants. Bayer sells radium-223 and is building a targeted alpha pipeline. Lantheus, GE HealthCare and Bracco Imaging lead in PET and SPECT diagnostics. Cardinal Health runs one of the largest U.S. networks of nuclear pharmacies, preparing unit doses for hospitals.

How hard is it to enter?

Entry barriers are high. Licensed facilities, reactor access and drug master files take years to secure, and hospitals rarely switch once a generator or tracer is qualified. Differentiation rests on supply security, a joined-up imaging and therapy portfolio, and on-time delivery of doses that decay by the hour.

How concentrated is the market?

We see the top ten suppliers holding well over half of global value, with the highest concentration in molybdenum-99 and lutetium-177 supply. Consolidation is pushing that higher: SHINE bought the Lantheus SPECT business, BWXT agreed to sell its medical isotope unit to Nordic Capital, and Curium is buying Lantheus. Fluorine-18, by contrast, stays fragmented across hundreds of local cyclotron sites.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.